Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Raymond Douglas
Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing
, /PRNewswire/ — Raymond Douglas, MD, PhD, a lead scientist behind the first FDA-approved treatment for thyroid eye disease (TED) and a 2026 ASOPRS Outstanding Contribution Award recipient, presented research at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 57th Annual Fall Scientific Symposium pointing to a new dosing approach for the patients most at risk of hearing side effects.
Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing
, /PRNewswire/ — Raymond Douglas, MD, PhD, a lead scientist behind the first FDA-approved treatment for thyroid eye disease (TED) and a 2026 ASOPRS Outstanding Contribution Award recipient, presented research at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 57th Annual Fall Scientific Symposium pointing to a new dosing approach for the patients most at risk of hearing side effects.
Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing
, /PRNewswire/ — Raymond Douglas, MD, PhD, a lead scientist behind the first FDA-approved treatment for thyroid eye disease (TED) and a 2026 ASOPRS Outstanding Contribution Award recipient, presented research at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 57th Annual Fall Scientific Symposium pointing to a new dosing approach for the patients most at risk of hearing side effects.
Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing
, /PRNewswire/ — Raymond Douglas, MD, PhD, a lead scientist behind the first FDA-approved treatment for thyroid eye disease (TED) and a 2026 ASOPRS Outstanding Contribution Award recipient, presented research at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 57th Annual Fall Scientific Symposium pointing to a new dosing approach for the patients most at risk of hearing side effects.
Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing
Prefer us on Google Facebook Twitter Bluesky WhatsApp SMS Email Print Save LOS ANGELES, Oct.
Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing
, /PRNewswire/ -- Raymond Douglas, MD, PhD, a lead scientist behind the first FDA-approved treatment for thyroid eye disease (TED) and a 2026 ASOPRS Outstanding Contribution Award recipient, presented research at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 57th Annual Fall Scientific Symposium pointing to a new dosing approach for the patients most at risk of hearing side effects.
Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing
LOS ANGELES, Oct. 12, 2026 - Raymond Douglas, MD, PhD, a lead scientist behind the first FDA-approved treatment for thyroid eye disease (TED) and a 2026 ASOPRS Outstanding Contribution Award recipient, presented research at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 57th Annual Fall Scientific Symposium pointing to a new dosing approach for the patients most at risk of hearing side effects.
The dual IGF-1R/IR blocker, Linsitinib, modulates human orbital fibroblast activity and proliferation
Abstract Aim: The insulin-like growth factor-1 receptor (IGF-1R) and its downstream signaling pathways drive proliferation, survival, and extracellular matrix production, representing key therapeutic targets in thyroid eye disease (TED). This novel in vitro study investigated the inhibitory effects of the dual IGF-1R/insulin receptor small-molecule inhibitor Linsitinib on orbital target cell activity, proliferation, and survival.
Raymond Douglas, MD, PhD, Is First in the Nation to Infuse Newly FDA-Approved Thyroid Eye Disease Treatment, LUMVOA ™ (veligrotug-vvze)
, /PRNewswire/ -- Raymond Douglas, MD, PhD, a world-renowned thyroid eye disease specialist and oculoplastic surgeon, is the first in the United States to administer LUMVOA ™ (veligrotug-vvze), an infusion therapy for thyroid eye disease (TED), post its FDA-approval. The milestone positions Dr. Douglas and his practice at the center of the next chapter in TED treatment following the FDA approval and launch of Lumvoa by Viridian Therapeutics in late June 2026.
Raymond Douglas, MD, PhD, Is First in the Nation to Infuse Newly FDA-Approved Thyroid Eye Disease Treatment, LUMVOA ™ (veligrotug-vvze)
, /PRNewswire/ -- Raymond Douglas, MD, PhD, a world-renowned thyroid eye disease specialist and oculoplastic surgeon, is the first in the United States to administer LUMVOA ™ (veligrotug-vvze), an infusion therapy for thyroid eye disease (TED), post its FDA-approval. The milestone positions Dr. Douglas and his practice at the center of the next chapter in TED treatment following the FDA approval and launch of Lumvoa by Viridian Therapeutics in late June 2026.
Raymond Douglas, MD, PhD, Is First in the Nation to Infuse Newly FDA-Approved Thyroid Eye Disease Treatment, LUMVOA ™ (veligrotug-vvze)
, /PRNewswire/ — Raymond Douglas, MD, PhD, a world-renowned thyroid eye disease specialist and oculoplastic surgeon, is the first in the United States to administer LUMVOA ™ (veligrotug-vvze), an infusion therapy for thyroid eye disease (TED), post its FDA-approval. The milestone positions Dr. Douglas and his practice at the center of the next chapter in TED treatment following the FDA approval and launch of Lumvoa by Viridian Therapeutics in late June 2026.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Raymond
Contact Raymond, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack